Table 1 Baseline characteristics
N | ||
|---|---|---|
Age (years) | 28 | 52.5 (22–75; 20.0) |
Sex (female), n (%) | 28 | 26 (92.9) |
Weight (kg) | 28 | 75.5 (50–105;24.3) |
Disease duration (months) | 28 | 31.5 (4–180) |
Medication | ||
Methotrexate, n (%) | 28 | 16 (57.1) |
Prednisolone, n (%) | 28 | 23 (82.1) |
Biologics naïve, n (%) | 25a | 15 (60.0) |
Clinical parameters | ||
DAS28 (CRP) | 28 | 4.61 (2.65–6.49; 1.75) |
Tender joint count (28-TJC) | 28 | 7.0 (0–22;8.75) |
Swollen joint count (28-SJC) | 28 | 2.5 (0–9;4.0) |
VAS patient (0–10 cm) | 28 | 6.0 (2.4–10;3.0) |
VAS physician (0–10 cm) | 28 | 4.0 (1.9–8.5;1.7) |
Morning stiffness (min.) | 28 | 30 (0–240;63.75) |
Laboratory parameters | ||
ESR (mm/h) | 28 | 27 (8–66;21.0) |
CRP (mg/l) | 27b | 5.4 (0.3–52;17.4) |
Fluorescence optical imagingc | ||
P1 | 28 | 1.5 (0–16;9.25) |
P2 | 28 | 19.5 (0–36;14.5) |
P3 | 28 | 1.0 (0–20;3.75) |
PVM | 28 | 5 (0–27;6.25) |
Musculoskeletal ultrasound (US7 Score) | ||
GS US7 synovitis (range 0–39) | 28 | 11 (4–22;8.25) |
PD US7 synovitis (range 0–39) | 28 | 2.0 (0–17;3.0) |
GS US7 tenosynovitis (range 0–5) | 28 | 0.5 (0–3;1.0) |
PD US7 tenosynovitis (range 0–15) | 28 | 0 (0–2;1.0) |